Leaderboard

3,5-diiodo-L-thyronine increases resting metabolic rate and reduces body weight without undesirable side effects. Antonelli A1, Fallahi P, Ferrari SM, Di Domenicantonio A, Moreno M, Lanni A, Goglia F. Department of Internal Medicine, University of Pisa, Pisa, Italy. alessandro.antonelli@med.unipi.it Abstract Recently, it was demonstrated that 3,5-diiodo-L-thyronine (T2) stimulates the resting metabolic rate (RMR), and reduces body-weight gain of rats receiving a high-fat diet. The aim of this study is to examine the effects of chronic T2 administration on basal metabolic rate and body weight in humans. Two euthyroid subjects volunteered to undergo T2 administration. Body weight, body mass index, blood pressure, heart rate, electrocardiogram, thyroid and liver ultrasonography, glycemia, total cholesterol, triglycerides, free T3 (FT3), free T4 (FT4), T2, thyroid stimulating hormone (TSH) and RMR were evaluated at baseline and at the end of treatment. RMR increased significantly in each subject. After continuing the T2 treatment for a further 3 weeks (at 300 mcg/day), body weight was reduced significantly (p<0.05) (about 4 percent), while the serum levels of FT3, FT4 and TSH, were unchanged. No side effects were observed at the cardiac level in either subject. No significant change was observed in the same subjects taking placebo. PMID: 22217997 n=2 FASEB J. 2005 Sep;19(11):1552-4. Epub 2005 Jul 12. 3,5-diiodo-L-thyronine powerfully reduces adiposity in rats by increasing the burning of fats. Lanni A1, Moreno M, Lombardi A, de Lange P, Silvestri E, Ragni M, Farina P, Baccari GC, Fallahi P, Antonelli A, Goglia F. Dipartimento di Scienze della Vita, Seconda Università di Napoli, Caserta, Italy. antonia.lanni@unina2.it Abstract The effect of thyroid hormones on metabolism has long supported their potential as drugs to stimulate fat reduction, but the concomitant induction of a thyrotoxic state has greatly limited their use. Recent evidence suggests that 3,5-diiodo-L-thyronine (T2), a naturally occurring iodothyronine, stimulates metabolic rate via mechanisms involving the mitochondrial apparatus. We examined whether this effect would result in reduced energy storage. Here, we show that T2 administration to rats receiving a high-fat diet (HFD) reduces both adiposity and body weight gain without inducing thyrotoxicity. Rats receiving HFD + T2 showed (when compared with rats receiving HFD alone) a 13% lower body weight, a 42% higher liver fatty acid oxidation rate, appoximately 50% less fat mass, a complete disappearance of fat from the liver, and significant reductions in the serum triglyceride and cholesterol levels (-52% and -18%, respectively). Thyroid hormones and thyroid-stimulating hormone (TSH) serum levels were not influenced by T2 administration. The biochemical mechanism underlying the effects of T2 on liver metabolism involves the carnitine palmitoyl-transferase system and mitochondrial uncoupling. If the results hold true for humans, pharmacological administration of T2 might serve to counteract the problems associated with overweight, such as accumulation of lipids in liver and serum, without inducing thyrotoxicity. However, the results reported here do not exclude deleterious effects of T2 on a longer time scale as well as do not show that T2 acts in the same way in humans. PMID: 16014396 n=rats

Running research: Heel-toe or toe-heel? December 12, 2019 Science News New research from La Trobe University suggests there is no evidence that changing a runner's strike pattern will help prevent injuries or give them a speed boost. In a bid to avoid shin splints, sore knees and other injuries, many runners have adopted a toe-to-heel trend, running on the balls of their feet. This is often encouraged by coaches and health professionals. However, in research out this week in Sports Medicine, La Trobe injury researcher and physiotherapist Dr Christian Barton found there is no evidence to suggest running on the front of your feet reduces injury risk or improves performance. "We analysed 53 studies which looked at the impact of forefoot, rearfoot and flatfoot running patterns on injury, running economy and running biomechanics," senior author of the study, Dr Barton said "Our comprehensive review suggests that telling someone to run on the ball of their foot instead of their heel may make them less efficient, at least in the short term. Additionally, there is no evidence either way on whether running on the balls of your feet reduces injury." Dr Barton said switching your running style shifts the body's loads but doesn't make them disappear. "Running toe-heel might help injuries at the knee, where loads are reduced. However, it may cause injuries to the feet and ankle, where loads are increased," Dr Barton said. "Put simply, when it comes to running style: If it ain't broke, don't fix it." Journal Reference: Laura M. Anderson, Daniel R. Bonanno, Harvi F. Hart, Christian J. Barton. What are the Benefits and Risks Associated with Changing Foot Strike Pattern During Running? A Systematic Review and Meta-analysis of Injury, Running Economy, and Biomechanics. Sports Medicine, 2019

Lancet. 2018 Aug 25;392(10148):637-649. doi: 10.1016/S0140-6736(18)31773-2. Epub 2018 Aug 16. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. O'Neil PM1, Birkenfeld AL2, McGowan B3, Mosenzon O4, Pedersen SD5, Wharton S6, Carson CG7, Jepsen CH7, Kabisch M7, Wilding JPH8. Obesity and Endocrinology Research, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK. Electronic address: j.p.h.wilding@liverpool.ac.uk. Abstract BACKGROUND: Obesity is a major public health issue, and new pharmaceuticals for weight management are needed. Therefore, we evaluated the efficacy and safety of the glucagon-like peptide-1 (GLP-1) analogue semaglutide in comparison with liraglutide and a placebo in promoting weight loss. METHODS: We did a randomised, double-blind, placebo and active controlled, multicentre, dose-ranging, phase 2 trial. The study was done in eight countries involving 71 clinical sites. Eligible participants were adults (≥18 years) without diabetes and with a body-mass index (BMI) of 30 kg/m2 or more. We randomly assigned participants (6:1) to each active treatment group (ie, semaglutide [0·05 mg, 0·1 mg, 0·2 mg, 0·3 mg, or 0·4 mg; initiated at 0·05 mg per day and incrementally escalated every 4 weeks] or liraglutide [3·0 mg; initiated at 0·6 mg per day and escalated by 0·6 mg per week]) or matching placebo group (equal injection volume and escalation schedule to active treatment group) using a block size of 56. All treatment doses were delivered once-daily via subcutaneous injections. Participants and investigators were masked to the assigned study treatment but not the target dose. The primary endpoint was percentage weight loss at week 52. The primary analysis was done using intention-to-treat ANCOVA estimation with missing data derived from the placebo pool. This study is registered with ClinicalTrials.gov, number NCT02453711. FINDINGS: Between Oct 1, 2015, and Feb 11, 2016, 957 individuals were randomly assigned (102-103 participants per active treatment group and 136 in the pooled placebo group). Mean baseline characteristics included age 47 years, bodyweight 111·5 kg, and BMI 39·3 kg/m2. Bodyweight data were available for 891 (93%) of 957 participants at week 52. Estimated mean weight loss was -2·3% for the placebo group versus -6·0% (0·05 mg), -8·6% (0·1 mg), -11·6% (0·2 mg), -11·2% (0·3 mg), and -13·8% (0·4 mg) for the semaglutide groups. All semaglutide groups versus placebo were significant (unadjusted p≤0·0010), and remained significant after adjustment for multiple testing (p≤0·0055). Mean bodyweight reductions for 0·2 mg or more of semaglutide versus liraglutide were all significant (-13·8% to -11·2% vs -7·8%). Estimated weight loss of 10% or more occurred in 10% of participants receiving placebo compared with 37-65% receiving 0·1 mg or more of semaglutide (p<0·0001 vs placebo). All semaglutide doses were generally well tolerated, with no new safety concerns. The most common adverse events were dose-related gastrointestinal symptoms, primarily nausea, as seen previously with GLP-1 receptor agonists. INTERPRETATION: In combination with dietary and physical activity counselling, semaglutide was well tolerated over 52 weeks and showed clinically relevant weight loss compared with placebo at all doses. PMID: 30122305 Weight loss of +10% in a year is hella impressive. This stuff is also now available as an oral formulation.

It's just my insecurities and frustrations trying to rip out of my chest No I guess it was a spasm. There was definitely a bulge in my chest. There are witnesses!

So you boned your way into a mental hernia?

No, you don't get it. You'd be at worst, petty bourgeoisie. But not even that since you're not part of the capitalist class who owns the means. That is generally reserved for owners who work beside labor. In reality, you're a prole just like me and everyone else here. If the revolution comes, we won't be executing people like you unless we get real, real far down the priority ladder (at least in my view leftism). But your love of rules bothers me but that's only on a personal level.

One of the reasons that I think Red Hat isn't awful as a place to work is that when we have our inevitable yearly re-org, it's all done out in the open. There's some stuff that goes on under the cone of silence, no doubt, but a good majority of it happens in front of us and with us taking part in the project over the course of the re-org.

The so-called Blue Zones are regions where there’s a high proportion of very old people, nonagenarians and centenarians. Is that really the truth about the Blue Zones? What's The Truth About Blue Zones The observation of individuals attaining remarkable ages, and their concentration into geographic sub-regions or ‘blue zones’, has generated considerable scientific interest. Proposed drivers of remarkable longevity include high vegetable intake, strong social connections, and genetic markers. Here, we reveal new predictors of remarkable longevity and ‘supercentenarian’ status. In the United States, supercentenarian status is predicted by the absence of vital registration. The state-specific introduction of birth certificates is associated with a 69-82% fall in the number of supercentenarian records. In Italy, which has more uniform vital registration, remarkable longevity is instead predicted by low per capita incomes and a short life expectancy. Finally, the designated ‘blue zones’ of Sardinia, Okinawa, and Ikaria corresponded to regions with low incomes, low literacy, high crime rate and short life expectancy relative to their national average. As such, relative poverty and short lifespan constitute unexpected predictors of centenarian and supercentenarian status, and support a primary role of fraud and error in generating remarkable human age records. Supercentenarians and the oldest-old are concentrated into regions with no birth certificates and short lifespans

Related drug, liraglutide is indicated for obesity, specifically coincident with HTN.

Yes, but you have to understand that short bowel causes malnourishment by rapid transit and malabsorption. Increasing the surface area and slowing transit will increase the amount of calories absorbed in an SBS patient irrespective of anorectic or thermogenic properties. One of the most common listed side effects of Teduglutide is “change in appetite”. An SBS patient could have a reduced appetite and still gain weight through enhanced absorption. For perspective my wife went from 5’7” and 90lbs to 100lbs over the past 6 months of use but she eats sparingly and gets nausea post-injection.

Amazon will be delivering some today. Not really expecting much since 'research' T3 and/or T4 doesn't do anything for me. The first time I used it (maybe 12 years ago) I lost weight like crazy. After that, it turns me into a hot sleeper at night, but doesn't budge the scale.

I bet you'd have to find a really edgy doc that you rx this for weight loss, though. I have an upcoming physical, so I might try to walk my guy down this path.

No hernia!

Bench 45x20 95x10 135x10 185x5 225x3 255x1 285x2x4S 285xAMRAP (x10) 235x10 195x10 145x15 Pec-deck flyes 120x10 130x10 140x10 Reverse pec-deck 110x15 120x10 130x10 140x5, 120x5 Triceps Hell Over 57.5x20 62.5x20 Under 47.5x20 52.5x20 Superset Low cable biceps curl and standing crunch 52.5x10 72.5x15 54x10 77.5x15 59x10 82.5x15 XXX 87.5x15 Seated concentration curl done strict and slow 25x10 30x10 35x10 25x10

Way way back in the day I used to love Biotest’s T-2 product; paired with MD6 was one of the leanest times of my life and I felt great throughout. I am tempted to give this a try again.

Yes, I know that feeling all too well. Rest up, Oz.

I feel you on that.

Squatengruben 45x10 135x10 185x5 225x5 275x3 315x1 380x2x4S 380xAMRAP (x10) 335x10 245x10 155x10 Sled 100x1 155x1 210x1 265x1 290x1 210x1 155x1 100x1 Need to get some ab work in...

Check out Kettle and Fire's Bone Broth Chili Their bone broth soups are also amazing. The Miso and Turmeric Ginger soups are on point.

https://www.amazon.com/Nutrition-Thyro-T2-Stimulant-Metabolism-Capsules/dp/B01J9713DM?SubscriptionId=AKIAILSHYYTFIVPWUY6Q&tag=duckduckgo-brave-20&linkCode=xm2&camp=2025&creative=165953&creativeASIN=B01J9713DM

19/12/10 BENCH A2S C2W4 PAUSE BENCH 135x5 185x5 225x5 275x2 300x6 <-- RPE 9.9 DB OHP 60x3x6 <-- RPE 5-6 DIPS (BW@242) +55x10,10 PULLUPS BWx10,10,9 LAT BAR TRICEP PUSHDOWNS 85x3x12 Great session. Aimed for 5, wanted 8, got 6. This is more than enough to bump my max up 5lbs, so I will do that for my next block. This is the beginning of something of a deload week, which really means the volume is cut, thus the low effort DB press and just 2 sets of dips. Those pullups were real nice and strong, surprisingly, especially after not having done them in a while.

I can't attribute the overall outcomes to any one particular ingredient, but I used to love the original (is there a new version, even?) Alpha-T2, which was a mix I believe of rauwolscine and 3,5-T2 (and methyl-synephrine, which I know I don't respond at all to). It was quite a powerful product when combined with (fasted) cardio. The only thing I didn't like about the product is it would give me this symptom I can only describe as strong heart pump echoes the first few days or so. From memory, I remember that an advantage of 3,5-T2 over 3,3-T2 is that 3,5-T2 doesn't cause endogenous T4/T3 shutdown, or at least not in like a 4-8 week setting, whereas 3,3-T2 did.

That's the big question in my mind. If the malaise is a broken, superficial reaction to exercise then I think it makes sense to push through it. I want to maintain as much muscle mass and fitness as possible until this hopefully passes. On the other hand, I worry that this is my body's way of telling me to knock it off because something is genuinely wrong. Latest round of blood tests came back. I don't have the raw numbers yet. The doctor says everything was normal except I have evidence of an EBV infection. This is the 3rd time in my life that I've had CFS symptoms with a positive EBV test. Going to take it easy for a month or two. Rest up and see if I improve. Might try to coordinate with a specialist to track down this EBV thing in further detail, but it's not exactly a treatable condition.

That escalated quickly. No company is perfect, but IMO it doesn't take much effort to be a decent place to work. Especially at large scale tech companies where the revenue per employee leaves plenty of margin for taking care of people. I'm ambivalent about the superficial perks like company parties, expensive off-site retreats, snack rooms stocked with junk food, ping pong tables, and the other perks that companies like to advertise. Just give me open communication, clear directives, market-rate pay, good health insurance, reasonable transparency, and an environment of mutual respect.

I have never seen a 950lb+ deadlift look so butter...

This is tough. There are scenarios in which, as God and Sanction are suggesting, the personal blowback could be quite severe. I have always pushed my senior leadership to lift the cone of silence on restructurings asap and have tended to have corporate knowledge transfer + succession plans in place, but the cone generally has a nestedness, and that nestedness is sometimes there for very good reasons.

So last night I was visiting the girl I'm seeing, and in the midst of our time together I felt pain and saw large protrusion around my upper right abdominal wall around my ribs. It was soft. I suspect it was just an aggressive spasm that pulled a rib out, but it could be a hernia. I'm trying to be seen by a doc but the fuckers are taking their time turning around a call. Hopefully it's not a hernia. Either way, this doesn't bode too well for my lifting. Of course this happens now, too.